Advances in the therapy of BRAFV600E metastatic colorectal cancer.
Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset with an approximate 8% incidence. In these patients, standard chemotherapy has limited efficacy, and the recent development of novel-targeted treatment regimens may significantly improve clinical outcome. Area covered: This review provides an overview of available data regarding advances in the first-line treatment of BRAFV600E metastatic CRC including patient tumors with microsatellite instability. The implications of BRAFV600E in earlier stage CRC are also discussed. Expert opinion: Recently, significant progress has been achieved in improving tumor response rates using a novel-targeted regimen in patients with BRAFV600E metastatic CRC. The implications of BRAFV600E in non-metastatic CRC are also becoming more evident and remains an area of ongoing investigation. The majority of CRCs with microsatellite instability high are sporadic and frequently harbor BRAFV600E. All patients with microsatellite instability high metastatic CRCs, irrespective of BRAFV600E, are candidates for immune checkpoint inhibitors. The optimal sequencing of treatment regimens for patients with BRAFV600E metastatic CRCs is an important area for future research.